How India Exports Repaglinide to the World

In the United States, repaglinide has been approved through multiple Abbreviated New Drug Applications (ANDAs). According to the FDA's Orange Book, there are 31 approved ANDAs for repaglinide, indicating a competitive generic market. Notably, Sun Pharmaceutical Industries, Inc. received approval for its ANDA on November 19, 2020. The absence of current import alerts related to repaglinide suggests compliance with FDA standards among Indian exporters. The substantial number of Indian exporters (41) underscores India's significant role in supplying repaglinide to the U.S. market.

In the European Union, repaglinide is subject to marketing authorization by the European Medicines Agency (EMA). The EMA's European Public Assessment Reports (EPARs) provide detailed information on approved medicinal products, including repaglinide. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and regulation of repaglinide. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to these regions, ensuring product quality and safety.

Repaglinide is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its importance in managing diabetes globally. The drug is also recognized in various pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality across different markets.

In India, repaglinide is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, repaglinide is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations.

The primary patents for repaglinide have expired, leading to increased generic competition. This has facilitated the entry of multiple generic manufacturers into the market, contributing to the drug's affordability and accessibility.

In June 2025, the NPPA conducted a review of antidiabetic drug prices, including repaglinide, to assess market trends and ensure fair pricing. In September 2025, the CDSCO issued updated guidelines for the bioequivalence studies of generic drugs, impacting repaglinide manufacturers seeking approval. In December 2025, the DGFT streamlined the export NOC process for pharmaceutical products, including repaglinide, to facilitate international trade.

These developments reflect the dynamic regulatory environment affecting the production, pricing, and export of repaglinide from India.

Repaglinide, a medication used to manage type 2 diabetes, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) is heavily reliant on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where approximately 70–80% of global KSM supply is controlled by China, making it a dominant player in the pharmaceutical raw materials market.

The reliance on Chinese KSMs introduces significant vulnerabilities into the supply chain. For instance, in September 2020, China increased the prices of key drug materials by 10–20%, impacting the cost structures of Indian pharmaceutical manufacturers. Such price fluctuations, coupled with potential export restrictions or geopolitical tensions, can disrupt the consistent supply of essential medications like Repaglinide.

Our proprietary trade data indicates a high supplier concentration for Repaglinide exports from India. The top five exporters account for 98.5% of the total export value, with AUROBINDO PHARMA LTD alone contributing 51.4%. This concentration poses a significant single-source risk; any operational or regulatory issues affecting these key suppliers could lead to substantial disruptions in the global supply of Repaglinide.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic manufacturing of critical APIs and KSMs. In October 2024, two greenfield plants were inaugurated under this scheme to produce essential molecules like Penicillin G and Clavulanic Acid, marking a step towards reducing import dependence. However, the effectiveness of these initiatives in diversifying the supplier base for Repaglinide remains to be seen.

Geopolitical tensions and conflicts have significantly impacted global shipping routes, leading to supply chain disruptions. The ongoing conflict in the Strait of Hormuz has halted oil tanker movements, affecting the distribution of pharmaceuticals from India. Approximately 3,200 ships are stalled within the Persian Gulf, causing worldwide logistical shortages and rising prices. Additionally, increased instability in the Red Sea and Suez Canal has forced companies to reroute ships around Africa’s Cape of Good Hope, adding delays and fuel surcharges.

Furthermore, the U.S. government's directive in August 2025 to stockpile a six-month supply of advanced pharmaceutical ingredients underscores the growing concern over supply chain vulnerabilities. This move aims to reduce dependency on foreign suppliers, particularly China, and highlights the strategic importance of securing pharmaceutical supply chains.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source for APIs and KSMs.

• Enhance Domestic Production: Invest in local manufacturing capabilities for critical raw materials to decrease reliance on imports.

• Strengthen Regulatory Compliance: Ensure all suppliers adhere to stringent quality standards to mitigate risks associated with regulatory violations.

• Develop Contingency Plans: Establish robust contingency strategies to address potential disruptions in shipping routes and geopolitical tensions.

• Monitor Geopolitical Developments: Stay informed about international events that could impact supply chains and adjust procurement strategies accordingly.

RISK_LEVEL: HIGH